Skip to main content

Physician Search


Displaying 1 - 1 of 1

DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors

Multiple Cancer Types

This is a Phase 1b / 2, multi-center, open label umbrella study of patients 12 years of age with recurrent or progressive solid tumors with alterations in the key proteins of the RAS / RAF / MEK / ERK pathway, referred to as the MAPK pathway..
Miscellaneous, Phase I
Berlin, Jordan